KRAS and BRAF mutations are considered mutually exclusive.3 Another important molecular feature is the adenomatous polyposis coli (APC) gene, a key tumour suppressor gene mutated in 45% to 81% of sporadic CRC cases.2 The gene discussed is KRAS; the disease is neoplasm.